Condition
Non-Muscle Invasive Bladder Neoplasms clinical trials and research
As of November 12, 2026, Find a Trial lists 5 Non-Muscle Invasive Bladder Neoplasms clinical trials that are recruiting, at sites in 29 countries (most in Italy (4), United States (4), Argentina (3)). By phase: Phase 3 (2), Phase 2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 29Countries
Newest Non-Muscle Invasive Bladder Neoplasms clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Real-world outcomes of TAR-200 for people with non-muscle invasive bladder cancer in the United States | — | Birmingham, Alabama and 22 other locations | Recruiting | Dec 30, 2025 |
| TAR-210 versus intravesical chemotherapy for high-risk non-muscle-invasive bladder cancer | Phase 3 | Sun City, Arizona and 114 other locations | Recruiting | Apr 9, 2025 |
| New treatment for high-risk non-muscle invasive bladder cancer | Phase 2 | Bakersfield, California and 88 other locations | Recruiting | Feb 18, 2025 |
| Comparing TAR-210 to standard chemotherapy for bladder cancer treatment | Phase 3 | Little Rock, Arkansas and 192 other locations | Recruiting | Mar 20, 2024 |
| Tracking quality of life and relapses in bladder cancer patients after surgery | — | Milan, MI | Recruiting | Dec 12, 2023 |
All recruiting trials (5)
-
Real-world outcomes of TAR-200 for people with non-muscle invasive bladder cancer in the United States
This project will see if TAR-200 helps people with non-muscle invasive bladder cancer stay disease-free longer after their first insertion during routine care in the U.S.
-
TAR-210 versus intravesical chemotherapy for high-risk non-muscle-invasive bladder cancer
This trial will test whether TAR-210 prevents cancer recurrence better than standard bladder instillation chemotherapy (mitomycin C or gemcitabine) in people with high-risk non-muscle-invasive bladder cancer who have FGFR mutations or fusions.
-
New treatment for high-risk non-muscle invasive bladder cancer
This study is testing a new treatment combining Intismeran autogene with BCG to see if it can help people with high-risk non-muscle invasive bladder cancer who haven't responded to standard BCG therapy.
-
Comparing TAR-210 to standard chemotherapy for bladder cancer treatment
This study is testing if a new treatment called TAR-210 can help people with intermediate-risk bladder cancer live longer without their cancer coming back compared to standard chemotherapy options.
-
Tracking quality of life and relapses in bladder cancer patients after surgery
This study is tracking how bladder cancer patients feel and whether their cancer comes back after surgery over the next 10 years.
Related topics
Quick answers
How many Non-Muscle Invasive Bladder Neoplasms clinical trials are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 29 countries. The most sites are in Italy (4 trials), United States (4 trials), Argentina (3 trials), Brazil (3 trials), France (3 trials). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 3: 2, Phase 2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.